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Abstract
Background: Cardiometabolic diseases (CMDs) are an important cause of mortality worldwide and the burden
associated with them is increasing in Sub-Saharan Africa. The tracking of mortality helps support evidence based
health policy and priority setting. Given the growing prevalence of non-communicable diseases in Zimbabwe, a
study was designed to determine the mortality attributable to CMDs in Zimbabwe.
Methods: The study design was a retrospective cross-sectional analysis of national mortality from 1996 to 2007,
collated by the Ministry of Health and Child Welfare in Zimbabwe. We employed generalized additive models to
flexibly estimate the trend of the CMD mortality and a logistic regression model was used to find significant factors
(cause of death according to the death certificate) of the CMD mortality and predict CMD mortality to 2040.
Results: CMDs accounted for 8.13 % (95 % CI: 8.08 % - 8.18 %) of all deaths during 1996 to 2007
(p = 0.005). During the study period CMD mortality rate increased by 29.4 % (95 % CI: 19.9 % - 41.1 %). The
association between gender and CMD mortality indicated female mortality was higher for diabetes (p < 0.001),
hypertensive disease (p < 0.001), CVD (p < 0.001) and pulmonary disease (p < 0.001), while male mortality was higher
for ischaemic (p = 0.010) and urinary diseases (p < 0.001). There was no gender difference for endocrine disease (p =
0.893). Overall, females have 1.65 % higher mortality than males (p < 0.001). CMD mortality is predicted to increase
from 9.6 % (95 % CI: 8.0 % - 11.1 %) in 2015 to 13.7 % (95 % CI: 10.2 % - 17.2 %) in 2040 for males, and from 11.6 %
(95 % CI: 10.2 % - 12.9 %) in 2015 to 16.2 % (95 % CI: 13.1 % - 19.3 %) in 2040 in females.
Conclusion: The findings of this study indicate a growing prevalence of CMDs and related mortality in Zimbabwe.
Health policy decisions and cost-effective preventive strategies to reduce the burden of CMDs are urgently
required.
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Background
Cardiometabolic disease (CMD) is an emerging term
that encompasses cardiovascular disease, diabetes and
metabolic syndrome (MetS). The primary components
of MetS include obesity, insulin resistance, dyslipidemia,
and hypertension [1–4], which are major risk factors for
diabetes, and vascular diseases including myocardial
infarction, stroke, chronic kidney disease, and ischemic
gangrene [1–4]. CMDs are becoming increasingly com-
mon in Sub-Saharan African (SSA) countries [5–7], with
the prevalence ranging from non-existent to as high as
about 50 % or even higher depending on the population
setting [8, 9]. The prevalence of CMDs in SSA is thought
to be driven by the departure from traditional African
lifestyles and diets in favour of Western lifestyles and di-
ets [8]. Changes to lifestyle including rapid urbanization,
reductions in occupational physical activity, increased
intake of highly processed foods and abdominal obesity
are considered risk factors for CMD [8]. Mortality attrib-
utable to CMDs could therefore be targeted through
public health interventions.
The pattern of morbidity and mortality in Zimbabwe,
like most of SSA, has been dominated by infectious and
parasitic diseases, nutritional deficiencies, obstetric causes
and perinatal conditions, as well as injury-related condi-
tions [9]. However, CMDs are placing an increasing bur-
den on health care systems in many countries in SSA
including Zimbabwe, with CMD mortality ranging from
17 % in Zimbabwe, Zambia and Mozambique to 34 % in
South Africa and 36 % in Cameroon [9]. Hypertension
was ranked first and diabetes ranked fourth (after asthma
and epilepsy) amongst the non-communicable disease
(NCD) outpatient visits recorded in Zimbabwean public
hospitals [10], and while infections are still a major health
burden in Zimbabwe, NCDs have also become a problem.
In Zimbabwe, cause of death statistics are the primary
data source for monitoring the health status and inform-
ing chronic disease priorities in the country [10]. How-
ever NCD mortality estimates for Zimbabwe have a high
degree of uncertainty because they are not based on any
systematically collected national NCD mortality data.
The estimates are based on a combination of African
country life tables, cause of death models, regional cause
of death patterns, and program estimates for some major
causes of death (not including NCDs) [11]. A Zimbab-
wean burden of disease study [12] illustrated the import-
ance of conducting this kind of analysis for a specific
country, rather than assuming that regional estimates
would provide plausible estimates, when it reported that
disease patterns in Zimbabwe differed substantially from
regional estimates. A meta-analysis study found the
pooled prevalence of diabetes to be 5.7 % and hyperten-
sion to be 30 % in Zimbabwe [13, 14]. The purpose of
this paper was to estimate the mortality attributable to
CMDs in Zimbabwe, using the death certificate forms
registered through the Zimbabwe birth and deaths regis-
try and assembled by the Zimbabwe National Statistics
Agency (Zimstat) for the total deaths in the country
covering the period 1996 to 2007.
Methods
Gender-specific mortality and population data from
Zimbabwe National Statistics Agency (Zimstat) and the
Ministry of Health and Child Care (MoHCC) in
Zimbabwe for the period 1996 to 2007 were available,
although data for 1998 were missing. Data were stored
on an electronic system in the Zimstat offices in Harare,
and downloaded after approval was granted by the
MoHCC. Gender-specific death rates for CMDs were
based on deaths with a mention of diabetes mellitus,
other endocrine & metabolic diseases, hypertensive dis-
ease, ischaemic heart disease, cardio and cerebrovascular
accidents, pulmonary circulation, other circulatory and
heart disease, and urinary system diseases (which in-
cludes chronic kidney disease) as the underlying cause
of death from the total deaths recorded from 1996 to
2007. The longitudinal nature of the data also allowed us
to investigate trends in CMD mortality.
Classification of the causes of death
Zimbabwe used the ninth revision of the International
Classification of Disease (ICD-9) coding from 1996 to
2003, and tenth revision ICD (ICD-10) coding from
2004 to 2007 [15, 16]. The codes collected for the causes
of death are listed in Table 1. Data using ICD-9 codes
were converted to ICD-10 codes with the ICD-10 Trans-
lator [17].
Statistical analysis
A Generalized Additive Model (GAM) was used to ana-
lyse the trend, as the relationship between mortality and
time was not linear. This model is suitable for exploring
the data and visualizing the relationship between the
outcome variable and the covariates [18]. A smoothing
function was used for summarizing the trend of the out-
come as a function of time adjusted for gender, where
the smoothing function does not assume a rigid form for
the dependence of outcome. A p-value of less than 5 %
was considered as statistically significant.
A logistic regression was used to predict CMD mortality
for the male and female population from 2015 to 2040.
The 25-year selected period is the most common length
of select period used for mortality projections [19], and
will assist in quantifying reductions in mortality for the
UN sustainable development health goals for 2030 [20].
We assumed that there would be no collinearity between
gender and time. The projections do not take explicit ac-
count of changing population demographics during the
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study period, age, geographic locations, standards of living,
socio-economic conditions of the population and access
to health care services. Additionally, trends in major risk
factors such as tobacco smoking, alcohol consumption
and overweight and obesity have not been accounted for.
Results
The population mortality from 1996 to 2007 is shown in
Table 2. A total of 942,319 deaths were registered from
1996 to 2007 (note that no records are available for
1998). Approximately one in ten deaths (8.13 % 95 % CI:
8.08 % - 8.18 %) was attributable to CMD. Over the
12 year study period, CMD mortality rate increased by
29.4 % (95 % CI: 19.9 % - 41.1 %).
The mortality rates of the seven causes of death com-
prising CMDs from 1997 to 2007 appeared to follow
similar patterns in males and females (Figs. 1 and 2).
Pulmonary heart disease and other diseases of the heart
and circulatory system, CVD, diabetes and hypertensive
diseases made the largest contribution to CMD mortal-
ity, with females having a higher mortality rate than
males. The results of the GAM analysis (Fig. 3) show the
trends of mortality for diabetes mellitus, other endocrine
& metabolic diseases, hypertensive disease, ischaemic
heart disease, cardio and cerebrovascular accidents, pul-
monary circulation, other circulatory and heart disease,
urinary system diseases, as well as the total CMD mor-
tality. The solid line in the middle represents the
smoothing trend line, while the dashed lines represent
the 95 % confidence interval of the trend.
The clear contrast in these figures is the substantial
cause-specific differences over the study period. For ex-
ample, diabetes mortality rose sharply until 1997, then
again from 2005, whereas endocrine mortality was low
from 1996 and rose sharply from 2002. Cardiovascular
deaths decreased steadily from 1996, but rise sharply from
2000. Finally, total CMD mortality shows a clear increase
peaking at 2006. The p-value for each cause of death is also
presented in Fig. 3 and shows a strong significance with the
smoothing trend, while the corresponding adjusted R2 value
shows a very high percentage of variation in the outcome,
explained by time and gender, demonstrating a strong rela-
tionship between mortality and the covariates. The GAM
analysis indicated that females had higher mortality rates for
diabetes (p < 0.001), hypertensive disease (p < 0.001), CVD
(p < 0.001) and pulmonary disease (p < 0.001) during the
Table 1 ICD-9 and ICD-10 codes for cause of death listed on death certificates
Cause of death ICD-9 ICD-10
Diabetes 249-251.2 E10-E14
Hypertensive diseases 401-405 I10-I15
Ishaemic Heart Disease 410-414 I20-I25
Cardio- and Cerebrovascular Disease 430-438 I60-I69
Pulmonary Heart Disease and other diseases of the heart and circulatory system 415-417, 420-429, 440-448, 451-459 I26-I28, I30-I52, I70-I99
Urinary systems Diseases 580-599 N00-N39
Endocrine and Metabolic Diseases 270-279 E15-E16, E70-E90







Crude mortality rate % Death accounted for by CMD
(/100,000) 95 % CI % 95 % CI
1996 6088 89207 11,846,110 753.0 748.1 - 758.0 6.8 6.7 - 7.0
1997 6422 85964 12,045,813 713.6 708.9 - 718.4 7.5 7.3 - 7.7
1999 7290 91517 12,384,727 739.0 734.2 - 743.7 8.0 7.8 - 8.2
2000 7352 96163 12,503,652 769.1 764.2 - 773.9 7.6 7.5 - 7.8
2001 7468 98946 12,586,763 786.1 781.2 - 791.0 7.5 7.4 - 7.7
2002 8098 99820 12,640,922 789.7 784.8 - 794.6 8.1 7.9 - 8.3
2003 6827 88946 12,673,103 701.8 697.2 - 706.5 7.7 7.5 - 7.9
2004 8929 103848 12,693,047 818.1 813.2 - 823.1 8.6 8.4 - 8.8
2005 8553 92516 12,710,589 727.9 723.2 - 732.6 9.2 9.0 - 9.4
2006 8958 95717 12,724,308 752.2 747.5 - 757.0 9.4 9.2 - 9.6
2007 8149 92185 12,740,160 723.6 718.9 - 728.2 8.8 8.7 - 9.0
Total Period (excl. 1998) 84134 1034829 8.13 8.08 - 8.18
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period. However, males had a higher mortality for ischaemic
(p < 0.00966) and urinary diseases (p < 0.001). There was no
gender difference for endocrine diseases (p= 0.893).
CMD mortality is predicted to increase from 9.6 %
(95 % CI: 8.0 % - 11.1 %) in 2015 to 13.7 % (95 % CI:
10.2 % - 17.2 %) in 2040 for males, and from 11.6 %
(95 % CI: 10.2 % - 12.9 %) in 2015 to 16.2 % (95 % CI:
13.1 % - 19.3 %) in 2040 in females (see Fig. 4).
Discussion
The pattern of CMD mortality increasing over the study
period from 1996 to 2007 is consistent with observations
that CMD prevalence is reaching epidemic proportions in
Africa [21]. Diseases of the urinary system, which include
renal/kidney disease, are often associated with cardiovas-
cular risk factors, including dyslipidemia, hypertension,
and smoking [22]. Zimbabwean males are nine times more
likely to consume tobacco products than females, which
could explain the higher mortality of urinary system dis-
eases (including kidney disease) in Zimbabwean males
[23]. There was no gender difference found in mortality
attributable to endocrine diseases, but there was a signifi-
cant increase in mortality from 2004. In 2004 the Zimbab-
wean government initiated its national Antiretroviral
therapy (ART) programme for HIV/AIDS (Human Im-
munodeficiency Virus/ Acquired Immune Deficiency
Syndrome) [24], however due to the political and eco-
nomic instability at the time, mass emigration of health
workers and inadequate availability of foreign exchange
reserves meant procurement and distribution systems for
drugs and supplies was fragmented [25]. The use of ART
has been associated with adverse endocrine dysfunction
[26], with adrenal insufficiency the most common HIV
endocrinopathy found present in 77 % of post-mortems
[27]. As Zimbabwean doctors do not always mention
cause of death as HIV/AIDS on death certificates due to
stigma, bias and underreporting [28, 29], this could
possibly explain the sharp increase in endocrine disease
mortality from 2004. Ischaemic heart disease has previ-
ously been found to be a less common cause of heart fail-
ure and a more limited problem in terms of burden in
SSA [30, 31], explaining why it made the lowest contribu-
tion to CMD mortality in our results.
The increased risk of CMD is multifaceted and includes
a combination of many factors such as urbanisation, HIV/
AIDS treatment, and tuberculosis (TB). Pulmonary heart
disease and CVD, made the largest contribution to CMD
mortality. This result supports existing literature, as the
percentage of premature deaths from CVDs is as high as
42 % in low-income countries [32]. Mortality attributable
to CVD and pulmonary heart disease could be at least



















































Fig. 2 The proportion of deaths in females due to CMDs categories, 1996-2007
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and tuberculosis. As Zimbabwe is experiencing an HIV/
AIDS epidemic [33], the use of ART to treat HIV has
led to an increase in metabolic dysfunction, including
dyslipidemia and lipodystrophy [34], both risk factors
for developing heart disease. Pulmonary hypertension,
cardiomyopathy and pericardial disease, generally re-
lated to TB which is highly prevalent in Zimbabwe
[33], are the most commonly reported cardiac mani-
festations in HIV/AIDS [34–36].
While this paper provides the first robust evidence of
increasing CMD mortality, it does raise the question: what
is causing the increase in CMD mortality in Zimbabwe?
Similar to many countries in SSA, significant social,
cultural, and economic factors are contributing to the
growing prevalence of obesity, hypertension and diabetes
in Zimbabwe. Due to urbanization, families and individuals
in SSA have shifted to more western, unhealthy diets con-
sisting of high caloric intake and large amounts of refined
Fig. 3 Estimate of smooth function of time adjusted for gender, evaluated at the observed time using the Generalized Additive Model
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carbohydrates and fats [37]. Causes of overweight and
obesity have been linked to the consumption of high cal-
oric food and sugar-sweetened beverages, of which sales of
sugar-sweetened beverages are increasing worldwide, par-
ticularly in low- and middle-income countries as a result of
heavy marketing [38, 39]. In Zimbabwe, the overall per-
centage of obesity in the population was 7 %, with 11.6 %
of women and 2.4 % of men obese [11].
Obesity is a major risk factor for a number of CMDs,
including hypertension, diabetes, and cardiovascular dis-
eases [40, 41].
The health effects of this dietary change are com-
pounded by the cultural expectations regarding food and
body image, as fatness is associated with health and
prosperity, and weight loss is generally undesirable be-
cause it raises suspicion that a person has a serious ill-
ness [42]. Furthermore, there are barriers to physical
exercise that make weight loss difficult. Research has
shown that physically inactivity is high in SSA [43] due
to rapid urbanisation and socio-economic transitions
[44, 45].
Another possible reason could be the absence of well-
developed programmes for identification, comprehen-
sive CMD risk assessment and management of high-
risk individuals in Zimbabwe. Community based and
high-risk prevention strategies and policies have been
shown to reduce circulatory system mortality rates in
developed countries, but also in some developing coun-
tries [46-49].
This study had limitations. Firstly, the utilization of
national death registry data are limited by the under- or
mis-reporting of specific cause of death on death certifi-
cates. Death certificates can be unreliable indicators of
the causes of mortality, and mortality associated with car-
diometabolic diseases are generally underestimated when
only a single cause of death is coded, as in Zimbabwe
[29, 50, 51].
Studies have reported that diabetes was listed as the
underlying cause of death for only 7.7 % of diabetic men
and 13.4 % of diabetic women [52, 53]. This could ex-
plain why the mortality rate for diabetes is lower than
CVD and pulmonary heart disease. Behavioural, medical
and socioeconomic factors have been shown to have a
significant increase on mortality [54, 55], and the lack of
these predictors in our mortality projection is a signifi-
cant limitation. Therefore the mortality statistics likely
underestimate the impact of cardiometabolic disease
related deaths in Zimbabwe over the study period.
Secondly, in Zimbabwe 67 % of the population resides
in rural areas, and it is likely a high proportion of all
deaths occurred at home due to the inability to access
healthcare services. Where only the mode of dying is re-
ported on the death certificates (for example, “natural
cause”) then a potentially wide range of different under-
lying causes are missed. The quality of the mortality data
is determined largely by the medical knowledge, diligence
and integrity of the certifying doctor, nurse or, in some
rural areas, traditional chiefs or headman.
Studies seeking to identify areas to optimize for ICD-10
specificity should replicate the application in ICD-9 and
analyze the results [51], as preliminary comparability ra-
tios by cause of death have indicated an effect in the rank-
ing of leading causes of death, as well as substantial
discontinuities in cause-of death trends, such as diseases
of the urinary system, resulting from implementing ICD–
10 [56]. As the coding practices differed over the study
period, this confers challenges in comparison and inter-
pretation of disease codes which in turn underestimates
the mortality of some of the diseases analyzed [57].
Conclusion
This study has found that deaths due to CMD increased
significantly over the period 1996-2007 in both males and
females in Zimbabwe, and our projections suggest CMD
mortality will substantially increase from 2015 to 2040.
The most significant needs involve educating and effect-
ively treating people with CMDs, with emphasis on co-
morbid conditions such as HIV and TB, to substantially
Fig. 4 Projected CMD mortality for males and females in Zimbabwe for the period 2015 to 2040
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reduce CMD-related mortality. Zimbabwe’s healthcare
system heavily focuses on tertiary care, with little attention
to prevention. Further research into CMD morbidity and
mortality in Zimbabwe is required to accurately address
the causes and specific areas for health policy prevention
strategies.
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